Proof-of-concept study backs Iomed's OcuPhor:
This article was originally published in Clinica
Executive Summary
Iomed says that a proof-of-concept animal study of its non-invasive, site-specific ophthalmic drug delivery system has produced promising results. The OcuPhor system delivered a potent antibiotic, amikacin, to both the front and back of the eye in amounts well within the human therapeutic range for the drug, reports the Salt Lake City, Utah firm. The OcuPhor device is being developed for the treatment of conditions, such as uveitis, bacterial and viral infections, age-related macular degeneration and diabetic retinopathy.